|Bid||2.1000 x 1800|
|Ask||2.1500 x 3000|
|Day's Range||2.0000 - 2.1180|
|52 Week Range||1.6500 - 10.8000|
|Beta (5Y Monthly)||3.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 13, 2020 - Apr 19, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.15|
Yesterday’s filing was only for the registration (not sale) of the final tranche of the $10M equity line financing vehicle facilitated by Lincoln Park Capital. This $10M equity line transaction was previously announced in the company’s 8-K filing on September 7, 2018 and approved by shareholders on December 20, 2018. In order to utilize the equity line, the company is required to register all shares in advance.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on Monday, January 20th at 5pm it will conduct a shareholder update call with regard to several strategic initiatives for 2020 as well as the current status of IV-cell and Hemescreen deployment and the diversification of our business model into the products sector. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760).
NEW HAVEN, CT / ACCESSWIRE / December 17, 2019 / Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the receipt of their first commercial order for IV-Cell from Northwell Health. Precipio estimates generating considerable six-figures in annual revenues to the company as the first midsize customer to adopt IV-Cell. Northwell Health is New York's largest private employer and health care provider, with a $12B operating budget, 23 hospitals and more than 750 outpatient facilities; and serving over 5.5 million patients annually.
NEW HAVEN, CT / ACCESSWIRE / December 4, 2019 / Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced the resignation of Samuel Riccitelli from the board of directors, and his replacement by Richard Sandberg. The transition was ratified at the company's recent board of directors meeting and is effective as of December 1st, 2019. Mr. Riccitelli decided to resign so that he can focus on his recently accepted position as the Chief Executive Officer of Pathnostics, a diagnostics company focused on improving antibiotic stewardship through better diagnosis and treatment selection for patients suffering from urinary tract infections.
NEW HAVEN, CT / ACCESSWIRE / November 14, 2019 / Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), announced a substantial biomarker project with a large healthcare company that will generate significant revenue over the next two quarters. Precipio expects the project to be completed by the end of Q1 2020. "We are pleased to see companies in the pharma sector continuing to value the testing expertise and technologies that Precipio can offer," said Stephen Miller, Precipio's Chief Commercial Officer.
NEW HAVEN, CT / ACCESSWIRE / November 14, 2019 / Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announced preliminary results shared by two independent laboratories conducting testing of IV-Cell Media in a side-by-side parallel study comparing it to the media currently used by these laboratories. Both laboratories conducted a multi-sample study to evaluate the clinical and operational performance of IV-Cell, as part of their assessment to convert to using IV-Cell exclusively.
NEW HAVEN, CT / ACCESSWIRE / November 4, 2019 / Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be hosting its Third Quarter 2019 corporate update call on Wednesday, November 13th at 5:30 PM ET. The conference call may be accessed by calling 844-695-5519 (international callers dial 1- 412-902-6760). All callers should ask for the Precipio Inc. conference call.
Partners physicians are teaching affiliates of Harvard Medical School, and Partners is a national leader in biomedical research. Partners Online Second Opinions is part of Partners HealthCare, a not-for-profit healthcare delivery network based in Boston, Massachusetts.
NEW HAVEN, CT / ACCESSWIRE / October 2, 2019 / Specialty diagnostics company Precipio, Inc. (NASDAQ:PRPO), will hold a shareholder update call where CEO Ilan Danieli will discuss the company's commercial progress. The conference call may be accessed by calling 1-844-695-5519 (international callers may dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Tennessee Oncology has selected Precipio’s HemeScreen RUO assay as its molecular testing assay for hematologic malignancies such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPD). TN Oncology’s laboratory has validated the test and will be performing the HemeScreen assay as a lab developed test (LDT) within their laboratory.
Despite early hopes to the contrary, it looks as though September is going to end up as a relatively flat month for my trading account. Although there was some strong action coming out of August that carried ...
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Micron Technology, Inc. (NASDAQ: MU ) shares ...
This includes extensive testing as well as side-by-side comparison to the laboratory’s existing process in order to ensure both consistent results, as well as superior performance of the products. Only once these and other important parameters are demonstrated, does a laboratory proceed to discuss purchasing this product and integrating it into their clinical operations. In the laboratories that have completed their clinical testing step, the next and final step is the agreement on commercial terms.
NEW HAVEN, Conn., Sept. 05, 2019 -- Specialty Diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today a major development toward expanding cancer patient access to.
NEW YORK, NY / ACCESSWIRE / August 21, 2019 / Precipio, Inc. (NASDAQ: PRPO ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 21, 2019 at 5:00 PM Eastern ...
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the results of three key performance metrics that together demonstrate the continued growth and positive impact of the sales force’s expansion improving pathology sales performance. Precipio’s management team has established several key metrics that quantify pathology sales team performance and highlight areas of opportunity. The metrics highlighted above track conversions and trends across the sales pipeline to evaluate our success in attracting, retaining and growing “high-value” customers via trials and repeat orders.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be hosting its Second quarter 2019 corporate update call on Wednesday, August 21st at 5:00 PM ET, following its recent filing of its Form 10-Q on August 9th, 2019 and the release of its financial results for the second quarter ending June 30, 2019. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call.
This also provides the company with unencumbered-by-insurance reimbursement, high-margin revenues which contribute to growing both the top and bottom lines. Pursuant to Precipio’s strategic plan led by Chief Strategy Officer Ori Karev, the Company determined that the optimal approach to penetrating non-US markets is to first promote our proprietary technologies.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced the initiation of a second development project with H3 Biomedicine that will include the creation of a targeted gene panel. The panel would be used by H3 Biomedicine for their ongoing clinical development programs. H3 Biomedicine was launched in 2011 with an unprecedented $200 million funding commitment from Eisai, a leading global pharmaceutical company pharmaceuticals company, plus additional funding for clinical programs.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides an update to its shareholders. First, we would like to address the business activities surrounding our new products, IV-Cell and HemeScreen. Both IV-Cell and HemeScreen are proprietary to Precipio and have patents pending.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has entered into an exclusive subcontracting manufacturing agreement with diagnostics manufacturing company Novamed for the production of Precipio’s proprietary IV-Cell media for an initial term of 3 years. Novamed’s extensive experience providing various reagents to companies such as Thermo Fisher and Abbott Laboratories, as well as favorable business terms reached, were all key to its selection as Precipio’s choice manufacturer. The lengthy review and negotiation process was completed this week, following an extensive, in-depth technical, manufacturing and logistics due diligence, in which Precipio carefully evaluated Novamed’s capabilities to manufacture and deliver the IV-Cell media to Precipio’s specifications.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today provides shareholders with three of the key pathology performance metrics tracked by the company to ensure continuous growth of the business. The company’s revenues are comprised of two key components.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that, as previously stated, Ilan Danieli, Precipio’s CEO, has enrolled in a plan to purchase Precipio’s common stock on the open market in accordance with Rule 10b5-1 of the Securities and Exchange Act of 1934. Rule 10b5-1 allows officers and directors to enter into written, prearranged stock trading plans for the purpose of purchasing (or selling) company stock on the open market when they are in possession of material non-public information. Once established, officers and directors have no discretion over purchase or sales of stock under the plan and the pre-planned trades shall be executed as prescribed by the plan without regard for any subsequent material non-public information that the plan participant may receive.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on May 15, 2019 the Company received a letter from Nasdaq informing the Company that it had regained compliance with the Bid Price Rule and the matter is now closed. The company's shares will continue to be traded on The Nasdaq Global Market under the symbol PRPO. “We are pleased with the confirmation from Nasdaq on our compliance, ensuring that our shareholders have stock that is traded on a reputable exchange such as Nasdaq,” said Ilan Danieli, Precipio’s Chief Executive Officer.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that yesterday, in accordance with established Nasdaq protocol, the company held a hearing regarding its recent steps undertaken by it in order to regain compliance with the minimum bid price of $1.00. The company presented a solid business plan before the Panel with strong growth prospects indicating to the Panel that we believe these measures will enable our share price to meet the requirements necessary to remain listed on the Nasdaq,” said Ilan Danieli, Precipio’s CEO.